Committee Print

[SHOWING THE TEXT OF H.R. 1520 AS FAVORABLY FORWARDED BY THE
SUBCOMMITTEE ON HEALTH ON MARCH 27, 2019]

116TH CONGRESS
1ST SESSION

H. R. 1520

To amend the Public Health Service Act to provide for the publication
of a list of licensed biological products, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 5, 2019

Ms. Eshoo introduced the following bill; which was referred to the Committee
on Energy and Commerce

A BILL

To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the “Purple Book Con-
5 tinuity Act of 2019”.
SEC. 2. PUBLIC LISTING.

Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) is amended by adding at the end the following:

“(9) PUBLIC LISTING.—

“(A) IN GENERAL.—

“(i) INITIAL PUBLICATION.—Not later than 180 days after the date of enactment of the Purple Book Continuity Act of 2019, the Secretary shall publish and make available to the public in a searchable, electronic format—

“(I) a list in alphabetical order of the nonproprietary or proper name of each biological product for which a biologics license under subsection (a) or this subsection is in effect, or that has been deemed to be licensed under this section pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009, as of such date of enactment;

“(II) the date of approval of the marketing application and the application number; and
“(III) the marketing or licensure status of the biological product for which a biologics license under subsection (a) or this subsection is in effect or that has been deemed to be licensed under this section pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009.

“(ii) Revisions.—Every 30 days after the publication of the first list under clause (i), the Secretary shall revise the list to include each biological product which has been licensed under subsection (a) or this subsection during the 30-day period.

“(iii) Patent information.—Not later than 30 days after patent information has been provided by the reference product sponsor to the subsection (k) applicant respecting a biological product included on the list published under this subparagraph, such information shall be provided to the Secretary, and the Secretary shall, in revisions made under clause (ii), include such information for such biological product.
“(iv) Listing of exclusivities.—

For each biological product included on the list published under this subparagraph, the Secretary shall specify each exclusivity period that is applicable and has not concluded under paragraph (6) or paragraph (7).

“(B) Withdrawal or suspension of licensure.—If the licensing of a biological product was withdrawn or suspended for safety, purity, or potency reasons, it may not be published in the list under subparagraph (A). If the withdrawal or suspension occurred after its publication in such list, the reference product sponsor shall notify the Secretary that—

“(i) the biological product shall be immediately removed from such list—

“(I) for the same period as the withdrawal or suspension; or

“(II) if the biological product has been withdrawn from sale, for the period of withdrawal from sale or, if earlier, the period ending on the date the Secretary determines that the with-
5
drawal from sale is not for safety, pu-

rity, or potency reasons; and

“(ii) a notice of the removal shall be

published in the Federal Register.”

5 SEC. 3. REVIEW AND REPORT ON TYPES OF BIOLOGICAL

PRODUCT PATENTS TO BE LISTED.

Not later than 3 years after the date of enactment
of this Act, the Secretary of Health and Human Services
shall—

(1) solicit public comment regarding the type of

information that should be included in the list re-
quired by paragraph (9) of section 351(k) of the
Public Health Service Act (42 U.S.C. 262(k)), as
added by section 2; and

(2) transmit to Congress an evaluation of such

comments, including any recommendations about the
types of information that should be included on or
removed from the list.